Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Tylan Magnusson, Luciano Costa, Smith Giri, Gayathri Ravi, Kelly Godby, Binod Dhakal, Bhagirathbhai Dholaria, Eva Medvedova, Natalie S. Callander, JoAnn Steele, Kathy Langley, Baylie Mullinax, Melissa Sentell, Stephen Horn, Candace Hill, Megan Boullion, Susan Bal

Blood (2023) 142 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2023-187343

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero

Blood (2023) 142 (Supplement 1): 96.

https://doi.org/10.1182/blood-2023-179152

Published: 2023

Journal Articles

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

Fredrik Schjesvold, Andrew Spencer, Yael C. Cohen, Enrique M Ocio, Jordi López-Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, Noriko Doki, Rebecca Kan, Karolina Kulec, Gina Trabucco, Stan Ye, Romain Sechaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab

Blood (2023) 142 (Supplement 1): 4752.

https://doi.org/10.1182/blood-2023-177908

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Blood (2023) 142 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2023-173849

Published: 2023

Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal

Blood (2023) 142 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2023-178735

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Natalie S. Callander, Vincent Ribrag, Paul G. Richardson, Ajay K. Nooka, Kevin Song, Katarina Uttervall, Monique C. Minnema, Katja Weisel, Hang Quach, Chang-Ki Min, Marc S. Ballas, Xiaofang Li, Nirav Ratia, Morrys Kaisermann, Beata Holkova, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 897.

https://doi.org/10.1182/blood-2021-152662

Published: 2021

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Susan Bal, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari, Luciano J. Costa

Blood (2021) 138 (Supplement 1): 483.

https://doi.org/10.1182/blood-2021-145533

Published: 2021

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Susan Bal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari

Blood (2021) 138 (Supplement 1): 481.

https://doi.org/10.1182/blood-2021-145494

Published: 2021

Journal Articles

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Blood (2021) 138 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2021-149028

Published: 2021

Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood (2021) 138 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2021-150998

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Muhammad Umair Mushtaq, Moazzam Shahzad, Muhammad Usman Zafar, Muhammad Arslan, Ezza Tariq, Naira Fatima, Syeda Sadia Bokhari, Javeria Shahani, Iqra Anwar, Sibgha Gull Chaudhary, Anurag K. Singh, Sunil Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk

Blood (2021) 138 (Supplement 1): 1848.

https://doi.org/10.1182/blood-2021-145632

Published: 2021

Journal Articles

Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Muhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, Muhammad Usman Zafar, Ezza Tariq, Anam Hamid, Ayna Serwat, Iqra Anwar, Sibgha Gull Chaudhary, Nausheen Ahmed, Sunil Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk

Blood (2021) 138 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2021-146696

Published: 2021

Journal Articles

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial

Sikander Ailawadhi, Patrick Stiff, Emad Ibrahim, Damian J. Green, Brea Lipe, Elizabeth H. Cull, Natalie S. Callander, John Friend, Jarrod Longcor, Kate Oliver

Blood (2021) 138 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2021-152682

Published: 2021

Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood (2021) 138 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2021-150232

Published: 2021

Journal Articles

Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)

Luciano J. Costa, Robert Frank Cornell, Natalie S. Callander, Saurabh Chhabra, Michaela Liedtke, Ankit Kansagra, Kelly N. Godby, Susan Bal, Smith Giri, Ehsan Malek, Yubin Kang, Ravi Vij, Saad Z. Usmani, Parameswaran Hari, Shaji Kumar

Blood (2021) 138 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2021-144387

Published: 2021

Journal Articles

Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Blood (2021) 137 (1): 61–74.

https://doi.org/10.1182/blood.2020007156

Published: 2021

Includes: Supplemental data

NARROW

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)

Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only